Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Actinium Pharmaceuticals, retaining the price target of $5.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors related to Actinium Pharmaceuticals’ promising developments in targeted radiotherapies. The company is advancing its ATNM-400 program, which has shown significant potential in preclinical models for treating hormone-resistant and HER2-resistant breast cancer, as well as non-small cell lung cancer and prostate cancer. These developments highlight the drug’s potential to address unmet needs in cancer treatment, particularly in cases where current therapies are ineffective.
Additionally, Actinium’s pipeline includes Actimab-A, which is progressing towards pivotal trials for acute myeloid leukemia, and Iomab-ACT, which is advancing in CAR-T conditioning trials. The company’s strategic approach to developing these therapies, combined with a valuation model that incorporates risk adjustments and a discount rate, supports a positive outlook and a 12-month price target of $5.00. These elements contribute to McCarthy’s confidence in the company’s growth prospects and the Buy rating for its stock.
McCarthy covers the Healthcare sector, focusing on stocks such as OS Therapies Incorporated, SCYNEXIS, and Neuphoria Therapeutics. According to TipRanks, McCarthy has an average return of -14.4% and a 33.20% success rate on recommended stocks.
In another report released on October 27, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.